Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial

Table 2 Mean differences of Liver enzymes and hematological parameters before and after

Variables		Group*	Mean ± SDVsMean±SD	P-Value
Aspartate Aminotransferase U/L	Baseline VS 24th Week	1	57.06 ± 48.71Vs 20.17 ± 7.70	0.08
Aspartate Aminotransferase U/L	Baseline VS 24th Week	2	34.5 ± 25.27 Vs 21.61 ± 8.23	0.07
Alanine Aminotransferase U/L	Baseline VS 24th Week	1	50.89 ± 44.08 Vs 20.78 ± 10.81	0.02
Alanine Aminotransferase U/L	Baseline VS 24th Week	2	40.5 ± 34.85 Vs 22.28 ± 11.92	0.06
Hemoglobin g/dl	Baseline VS 24th Week	1	10.53 ± 1.61 Vs 10.31 ± 1.69	0.70
Hemoglobin g/dl	Baseline VS 24th Week	2	11.51 ± 1.14 Vs 10.02 ± 1.712	0.002
White Blood Cells ×10³/mm3	Baseline VS 24th Week	1	6.33 ± 1.94 Vs 5.78 ± 1.16	0.37
White Blood Cells ×10³/mm3	Baseline VS 24th Week	2	6.44 ± 1.91 Vs 6.61 ± 1.64	0.78
Platelets ×10³/mm3	Baseline VS 24th Week	1	163.27 ± 65.90Vs 172.94 ± 62.74	0.61
Platelets ×10³/mm3	Baseline VS 24th Week	2	175.44 ± 40.11 Vs 184.89 ± 53.82	0.58
Paired t-test was used to assess the significance

ISSN: 1471-2369